publicHealth Canada · Canada · Updated Jun 25, 2026
Addition of Donanemab, Islatravir, and Pegzilarginase to Prescription Drug List
MAHs must implement safety monitoring protocols and ensure compliance with reporting obligations associated with the newly classified prescription drugs.
Country ComplianceLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward